Discussing NanoMabs as a Modular Platform for Next-Generation Bispecific & NanoMab-Drug Conjugates

• Defining the medical and technical unmet needs in bispecific antibodies and ADCs
• Addressing the unmet needs through NanoMab (nanobody-based) solutions
• Outlining the potential market impact and future implications of NanoMab-enabled therapeutics

Speakers:

Seung-Yong Seong

Chief Executive Officer

Shaperon